title: Reduced relative dose intensity of primary chemotherapy does not influence prognosis of patients with Hodgkin lymphoma.
abstract: OBJECTIVE
  A retrospective analysis of patients with Hodgkin lymphoma (HL) was performed to assess their outcome regarding relative dose intensity (RDI) of chemotherapy administered in primary treatment.
  
  
  METHODS
  A total of 194 patients were divided into three groups with different RDI of primary chemotherapy (100%, 90-99% and <90%). Reduced RDI in two groups (90-99% and <90%) was caused by the delay of the interval between the administration of some chemotherapeutic courses. The probability of complete remission (CR), disease relapse, event-free survival (EFS) and overall survival (OS) as the basic parameters of patient outcome were statistically compared.
  
  
  RESULTS
  Multivariate analysis showed here were no significant differences in probability of CR (HR 0.9, 95% CI [0.75-1.08], P=0.5), risk of relapse (HR 1.34, 95% CI [0.92-1.94], P=0.11) or death (HR 1.52, 95% CI [0.94-2.5], P=0.13). There were also no significant differences in probability of EFS (mean 13 vs. 10 vs. 12 years, P=0.17; HR 1.54, 95% CI [0.91-2.6], P=0.22) or OS (mean 15 vs. 13 vs. 14 years, P=0.13; HR 1.52, 95% CI [0.93-2.5], P=0.13).
  
  
  CONCLUSIONS
  We found no significant impact of primary chemotherapy delay resulting in reduced RDI on outcome in HL patients.
authors.affiliation: Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.
authors.forename: Ludek
authors.initials: L
authors.lastname: Raida
authors.forename: Tomas
authors.initials: T
authors.lastname: Papajik
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Rusinakova
authors.forename: Vit
authors.initials: V
authors.lastname: Prochazka
authors.forename: Edgar
authors.initials: E
authors.lastname: Faber
authors.forename: Dana
authors.initials: D
authors.lastname: Cahova
authors.forename: Pavel
authors.initials: P
authors.lastname: Tucek
authors.forename: Karel
authors.initials: K
authors.lastname: Indrak
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents